Why Merck Stock Is Trading Higher Today

Merck & Co Inc's MRK Q1 sales reached $14.49 billion, down 9% Y/Y, beating the consensus of $13.79 billion.

Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding Lagevrio and the impact of foreign exchange, growth was 15%.

Pharmaceutical sales decreased by 10% to $12.72 billion, primarily due to lower sales in virology, mainly attributable to Lagevrio, and diabetes, partially offset by growth in oncology, vaccines, and hospital acute care.

Lagevrio Q1 sales declined 88% Y/Y to $392 million. Ketruda sales grew 20% to $5.8 billion. Gardasil/Gardasil 9 sales grew 35% to $2.0 billion.

Adjusted EPS of $1.40 also surpassed the analysts' estimate of $1.32 and declined 35% Y/Y.

Also Read: Merck Acquires Prometheus Biosciences For $10.8B, Strengthening Its Immunology Pipeline.

Moderna Inc MRNA and Merck's cancer vaccine exhibited positive results against relapse for melanoma patients.

About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone.

2023 Guidance: Merck has raised and narrowed FY23 adjusted EPS guidance to $6.88-$7.00 compared to prior guidance of $6.80-$6.95 and consensus of $6.91.

Merck anticipates FY23 sales Of $57.7-$58.9 billion compared to previously expected $57.2-$58.7 billion and the consensus of $58.28 billion.

Price Action: MRK shares are up 2.29% at $116.03 during the premarket session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!